Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999788 | 0.84 | ALPL (0.53) | ALPLSLC22A12SLC40A1PTGES2BRD4 | |
| SCHEMBL8229520 | 0.83 | ALPL (0.52) | ALPLSLC22A12SLC40A1PTGES2BRD4 | |
| SCHEMBL28312855 | 0.83 | SLC22A12 (0.54) | ALPLSLC22A12SLC40A1PTGES2BRD4 | |
| SCHEMBL10154346 | 0.83 | ALPL (0.52) | ALPLSLC22A12SLC40A1PTGES2BRD4 | |
| SCHEMBL6735794 | 0.81 | ALPL (0.51) | ALPLSLC22A12SLC40A1PTGES2BRD4 | |
| SCHEMBL29469931 | 0.80 | PTGES2 (0.55) | ALPLSLC22A12SLC40A1PTGES2CA2 | |
| SCHEMBL692280 | 0.80 | PTGES2 (0.55) | ALPLSLC22A12SLC40A1PTGES2CA2 | |
| SCHEMBL11101002 | 0.80 | MRGPRX1 (0.50) | ALPLSLC22A12SLC40A1PTGES2BRD4 | |
| SCHEMBL128257 | 0.80 | CASP1 (0.42) | MRGPRX1MAPTCA2HTR6 | |
| SCHEMBL30695942 | 0.80 | CASP1 (0.42) | MRGPRX1MAPTCA2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050014841-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2005-01-20 | — | — | US | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| US-6809119-B2 | FOR USE AS AS NEURO-PROTECTIVE AGENTS FOR THERAPY OF CONDITIONS SUCH AS STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE | WARNER-LAMBERT COMPANY LLC | 2004-10-26 | — | — | US | claimed |
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2003-08-07 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
| US-9115065-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses | Kineta, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9067873-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Kineta Four, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8664274-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8658697-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-6809119-B2 | FOR USE AS AS NEURO-PROTECTIVE AGENTS FOR THERAPY OF CONDITIONS SUCH AS STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE | WARNER-LAMBERT COMPANY LLC | 2004-10-26 | — | — | US | disclosed |
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2003-08-07 | — | — | US | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2003045902-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1314723-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | ALPL 1431/4885SLC22A12 421/4885SLC40A1 3063/4885 |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | ALPL 3412/4885SLC22A12 1000/4885SLC40A1 687/4885 |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | ALPL 1241/4885SLC22A12 350/4885SLC40A1 2943/4885 |
| US-20050014841-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | ALPL 1431/4885SLC22A12 421/4885SLC40A1 3063/4885 |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | ALPL 3412/4885SLC22A12 1000/4885SLC40A1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.